In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

This book focuses on putting successful molecular strategies into practice for the treatment of gynecologic cancer. It approaches research into the pathology and treatment of gynecologic oncology from both clinical and experimental perspectives. New insights made possible by the introduction of advanced technologies into the field are presented. This new volume will be necessary reading for clinicians and experimental researchers alike.

Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.

This practical reference book provides up-to-date, evidence-based multidisciplinary guidelines on the epidemiology, biology, diagnosis, and treatment of endometrial cancer. Individual chapters focus on topics such as hormonal interactions, cancer prevention, genetic classification and its clinical applications. Recent advances in diagnostic methods are described. The treatment-oriented chapters include coverage of the roles of lymphadenectomy and sentinel node dissection, surgical complications, radiation techniques, and chemotherapy in early-stage disease. Treatment options in advanced disease, including hormonal therapy and targeted therapy, are considered separately, as is the management of rare tumor types. The authors are international key opinion leaders. Summaries of the ESMO/ESGO/ESTRO guidelines on management are included. Each clinical chapter ends with a summary of recommendations with the level of evidence.

Genomic sequencing technologies have augmented the classification of cancer beyond tissue of origin and towards a molecular taxonomy of cancer. This has created opportunities to guide treatment decisions for individual patients with cancer based on their cancer’s unique molecular characteristics, also known as precision cancer medicine. The purpose of this text will be to describe the contribution and need for multiple disciplines working together to deliver precision cancer medicine. This entails a multi-disciplinary approach across fields including molecular pathology, computational biology, clinical oncology, cancer biology, drug development, genetics, immunology, and bioethics. Thus, we have outlined a current text on each of these fields as they work together to overcome various challenges and create opportunities to deliver precision cancer medicine. As trainees and junior faculty enter their respective fields, this text will provide a framework for understanding the role and responsibility for each specialist to contribute to this team science approach.